GenomOncology Collaborates With Roswell Park Cancer Institute on Informatics Solution for Next-Generation Sequencing
WESTLAKE, Ohio, Feb. 11, 2014 /PRNewswire/ -- GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
(Logo: http://photos.prnewswire.com/prnh/20140204/CL58248LOGO)
"The challenges of translating the vast amounts of data from next-generation sequencing into a resource that can be easily and effectively incorporated into clinical and research programs are significant," said Dr. Carl Morrison, Executive Director of the Center for Personalized Medicine at Roswell Park. "We need next-generation tools that will help us to deliver the best and most appropriate therapies to our patients through a streamlined process."
GenomOncology and RPCI are working together to develop a software platform that integrates laboratory information management systems, electronic health records, information technology and bioinformatics and that provides a workflow enabling genomic analysts and pathologists to create actionable reports.
GenomOncology will be demonstrating this software platform at two upcoming conferences, Advances in Genome Biology & Technology (AGBT) in February and United States & Canadian Academy of Pathology (USCAP) in March.
About Roswell Park Cancer Institute
The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email [email protected]. Follow Roswell Park on Facebook and Twitter.
About GenomOncology
GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed GO Clinical WorkbenchTM, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient's tumor genome into an actionable clinical report. GenomOncology's research platform, GenomAnalyticsTM, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company's website at www.genomoncology.com.
For more information regarding this announcement, please contact:
Jane Krug, PR Contact
Phone: 504-390-5935
Email: [email protected]
SOURCE GenomOncology
Share this article